P2RY12 and atrial fibrillation: The 2021 ACC/AHA/SCAI guideline additionally recommends that choice of a DOAC over warfarin is reasonable to reduce bleeding risk in patients with atrial fibrillation taking oral anticoagulant therapy and DAPT or P2Y12 inhibitor monotherapy.8